← Evidence map

ArticleMedComm2026

Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis.

Peng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papercites it

Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. | OpenQuestion